Antibody Test Kits
We thank you for your interest in Kantaro’s SARS-CoV-2 IgG Antibody Test Kit. Please discuss with your physician about ordering a test from your local testing facility.
Kantaro’s groundbreaking COVID-19 antibody tests will tell you the number of antibodies you have, making for more accurate, reliable and measurable results so you can manage your health and well-being.
Accurate
- Unlike most other tests, which just tell you whether you are positive/negative for COVID-19 antibodies, Kantaro’s test tells you the number of potentially neutralizing (anti-virus) antibodies in your system, which can give you a more precise understanding of your health and well-being, including your likelihood of re-infection.
- Knowing the amount of anti-virus antibodies you have — your antibody number — is the first step towards an informed future for you, your family and your community.
Proven
- Mount Sinai developed the technology underlying Kantaro’s kits during the height of the COVID-19 outbreak in New York City, designing the test to set the standard in antibody testing.
- As of December 2020, Mount Sinai has successfully used the antibody testing technology now found in the Kantaro kit over 80,000 times across a highly diverse population.
Accessible
- We believe everyone deserves access to important information about their health, so the Kantaro antibody test is designed to be easily used in laboratories all over the world.
- Because Kantaro’s antibody test allows you to monitor the amount of antibodies you have, we encourage you to get our test more than once.
- With your Kantaro test results, you can do your part to help the world recover from COVID-19 by donating plasma through the Mount Sinai Health System.
The Kantaro test is available at the Mount Sinai Health System for individuals volunteering to donate convalescent plasma, as well as healthcare workers and first responders. To learn more, please visit Mount Sinai’s Convalescent Plasma Program website. If you are interested in donating plasma, please complete Mount Sinai’s COVID-19 Plasma Collection Center pre-screening questionnaire.
Video Gallery
Kantaro’s SARS-CoV-2 IgG Antibody Test Kit is based on underlying technology invented at the Mount Sinai Health System. Below, you will learn from world-renowned experts in virology, infectious diseases and technology development at Mount Sinai as they share insight into the significance of antibody testing and how antibodies impact our individual health and that of our global community. These short videos provide relevant information for anyone who is curious about understanding antibody tests and their importance in the fight against COVID-19.
The Mount Sinai Antibody Test, the underlying technology for the Kantaro Kit, was developed and has been performed on over 80,000 patients by the Clinical Laboratories of The Mount Sinai Hospital. The Mount Sinai Antibody Test received FDA emergency use authorization (EUA) for semi-quantitative use on November 24, 2020, and qualitative use on April 15, 2020. The New York State Department of Health (NYSDOH) announced EUA for quantitative use on September 17, 2020, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood. Kantaro also received CE marking in the European Union on October 26, 2020. Kantaro is a joint venture between Mount Sinai and RenalytixAI.
What is the Mount Sinai antibody test and how can it provide insight into COVID-19 health status?
Speaker: Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at Mount Sinai
How did Mount Sinai utilize its antibody test to treat severely ill COVID-19 patients?
Speaker: Nicole Bouvier, MD, Associate Professor of Medicine and Infectious Diseases, Icahn School of Medicine at Mount Sinai
What are the other use cases for the Mount Sinai antibody test?
Speaker: Erik Lium, PhD, President, Mount Sinai Innovation Partners, Chief Commercial Innovation Officer, Mount Sinai Health System
Is there a relationship between COVID-19 antibody titers and immunity?
Speaker: Florian Krammer, PhD, Professor of Microbiology, Icahn School of Medicine at Mount Sinai
What is the difference between COVID-19 rapid testing and the Mount Sinai antibody test?
Speaker: Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at Mount Sinai
There's Power in Numbers. Know Yours: Kantaro’s SARS-CoV-2 Antibody Test
COVID-SeroKlir, Kantaro’s semi-quantitative SARS-CoV-2 IgG antibody test kit based on Mount Sinai technology, measures both the presence or absence of COVID-19 antibodies, as well as a numerical result for the level of antibodies in an individual.
Please check this website for updates.
You may also consult your physician about obtaining the test.
To learn more about Mount Sinai, visit:
To find information on Mount Sinai’s response to COVID-19, please visit the Mount Sinai COVID-19 Facts and Resources page.